Last Updated: September 28, 2026

ENOXACIN - Generic Drug Details

Name: ENOXACIN Generic Launch, Drug Patent, and Exclusivity Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

What are the generic drug sources for enoxacin and what is the scope of patent protection?

Enoxacin is the generic ingredient in one branded drug marketed by Sanofi Aventis Us and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for ENOXACIN

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	3
Raw Ingredient (Bulk) Api Vendors:	105
Clinical Trials:	7
DailyMed Link:	ENOXACIN at DailyMed

Recent Clinical Trials for ENOXACIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Utah	Phase 2
Ohio State University	Phase 2
Weizmann Institute of Science	Phase 1/Phase 2

See all ENOXACIN clinical trials

Medical Subject Heading (MeSH) Categories for ENOXACIN

Anti-Bacterial Agents
Cytochrome P-450 CYP1A2 Inhibitors
Topoisomerase II Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for ENOXACIN

J01MA	Fluoroquinolones
J01M	QUINOLONE ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for ENOXACIN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	PENETREX	enoxacin	TABLET;ORAL	019616-005	Dec 31, 1991		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Sanofi Aventis Us	PENETREX	enoxacin	TABLET;ORAL	019616-004	Dec 31, 1991		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for ENOXACIN

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	PENETREX	enoxacin	TABLET;ORAL	019616-005	Dec 31, 1991	4,359,578	⤷ Start Trial
Sanofi Aventis Us	PENETREX	enoxacin	TABLET;ORAL	019616-004	Dec 31, 1991	4,352,803	⤷ Start Trial
Sanofi Aventis Us	PENETREX	enoxacin	TABLET;ORAL	019616-005	Dec 31, 1991	4,352,803	⤷ Start Trial
Sanofi Aventis Us	PENETREX	enoxacin	TABLET;ORAL	019616-004	Dec 31, 1991	4,442,101	⤷ Start Trial
Sanofi Aventis Us	PENETREX	enoxacin	TABLET;ORAL	019616-004	Dec 31, 1991	4,359,578	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.